Urinary Clara Cell Protein in Kidney Transplant Patients: A Preliminary Study

Area of Science:

• Nephrology
• Transplantation Medicine
• Biomarker Discovery

Background:

• Kidney transplantation (KT) is a life-saving procedure, but recipients are susceptible to complications.
• Proximal tubular dysfunction (PTD) is a significant concern in KT patients.
• Clara cell protein 16 (CC16) is emerging as a novel biomarker for PTD.

Purpose of the Study:

• To investigate the urinary excretion of CC16 in kidney transplant recipients.
• To assess CC16 as a potential marker for PTD in the KT population.
• To compare CC16 levels with other established markers of tubular dysfunction.

Main Methods:

• A cohort of 50 kidney transplant (KT) patients and 10 healthy controls were studied.
• Urinary concentrations of CC16, β2-microglobulin (β2m), and N-acetyl-glucosaminidase (NAG) were measured.
• Correlation analysis was performed with glomerular filtration rate (GFR) and urinary albumin.

Main Results:

• KT patients exhibited significantly higher urinary levels of CC16, β2m, and NAG compared to controls (P < .001).
• Elevated CC16 was detected in 71% of KT patients, often even with preserved GFR (>60 mL/min).
• Urinary CC16 levels positively correlated with urinary albumin, NAG, and β2m.

Conclusions:

• PTD is highly prevalent in kidney transplant recipients.
• Urinary CC16 excretion is significantly increased in KT patients, highlighting its potential as a PTD marker.
• Further research is warranted to establish the clinical utility of CC16 in managing KT patients.